Literature DB >> 3025361

[3H]neurokinin B and 125I-Bolton Hunter eledoisin label identical tachykinin binding sites in the rat brain.

L Bergström, Y Torrens, M Saffroy, J C Beaujouan, S Lavielle, G Chassaing, J L Morgat, J Glowinski, A Marquet.   

Abstract

[3H]Neurokinin B ([3H]NKB) of high specific activity (75 Ci/mmol) was synthesized for study of its binding to crude synaptosomes from the rat cerebral cortex. The specific binding of [3H]NKB (75% of total binding) was temperature dependent, saturable, and reversible. Scatchard analyses and Hill plots showed the existence of a single population of noninteracting binding sites (KD = 4.3 nM; Bmax = 123 fmol/mg of protein). Competition studies indicated the following rank order of potencies among tachykinins: NKB greater than eledoisin (E) greater than kassinin greater than physalaemin greater than neurokinin A (NKA) greater than substance P (SP), a result suggesting that NKB might be the endogenous ligand for [3H]NKB binding sites. It is of interest that 127I-Bolton Hunter (BH) NKA (127I-BHNKA) was much more potent than NKA in inhibiting the specific binding of [3H]NKB, which raises certain questions concerning the use of 125I-BHNKA as a ligand for NKA binding sites in the brain. These results, as well as those obtained with different SP analogues, show a close similarity to those obtained previously with 125I-BHE binding to cortical synaptosomes. This suggested that the two ligands labeled identical binding sites. In addition, using either [3H]NKB or 125I-BHE as ligands, similar displacement curves were obtained with increasing concentrations of NKB and 127I-BHE. The similarity of the [3H]NKB and 125I-BHE binding sites was further confirmed by comparison of their localization on rat brain sections by autoradiography. The distribution of binding sites for [3H]NKB and 125I-BHE was identical throughout the brain, and the highest density of binding sites for the two ligands was found in layers IV and V of the cerebral cortex, the paraventricular nucleus of the hypothalamus (magnocellular part), and the ventral tegmental area.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3025361     DOI: 10.1111/j.1471-4159.1987.tb13136.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

2.  A study on the rat brain receptors for tachykinins and muramyl peptides.

Authors:  E M Lazakovich; A A Kaydalov; I E Kasheverov; V I Tsetlin
Journal:  J Protein Chem       Date:  1989-06

3.  Interactions between tachykinins and diverse, human nicotinic acetylcholine receptor subtypes.

Authors:  R J Lukas; C M Eisenhour
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

4.  gamma-Preprotachykinin-(72-92)-peptide amide: an endogenous preprotachykinin I gene-derived peptide that preferentially binds to neurokinin-2 receptors.

Authors:  T V Dam; Y Takeda; J E Krause; E Escher; R Quirion
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes.

Authors:  S Guard; S P Watson; J E Maggio; H P Too; K J Watling
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

6.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.

Authors:  C Tschöpe; P Picard; J Culman; A Prat; K Itoi; D Regoli; T Unger; R Couture
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.

Authors:  H Morimoto; M Murai; Y Maeda; D Hagiwara; H Miyake; M Matsuo; T Fujii
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

10.  Neurokinin3-receptors are linked to inositol phospholipid hydrolysis in the guinea-pig ileum longitudinal muscle-myenteric plexus preparation.

Authors:  S Guard; K J Watling; S P Watson
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.